← GLP-1 receptor agonists × glycemic control

TrialDiabetes care2016

Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.

Michael Nauck et al.PubMed ↗Publisher ↗

The primary results report of NCT01973231.

What the trial testedrandomised · 404 people · 2016

Randomised comparison

Probably lowered glycemic control

−1.15mmol/L−1.50 to −0.80

As reported

difference −1.15 mmol/L, 95% CI −1.50 to −0.80

Not counted

Probably lowered glycemic control

−0.62percentage points−0.80 to −0.40

As reported

difference −0.62 %, 95% CI −0.80 to −0.40

Two numbers in the abstract

the abstract, start to end

… (estimated treatment difference -0.62% [95% CI -0.8; -0.4]; P < …

… (estimated treatment difference -1.15 mmol/L [95% CI -1.5; -0.8]; P < …

← favours treatmentfavours comparator →
could be chance
Glycemic control
−0.62−0.80 to −0.40
Glycemic control
−1.15−1.50 to −0.80
GLP-1 receptor agonistsGlycemic control
1 / 4

52 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT01973231phase 4404 enrolled2013this paper is its primary report
Full record →Abstract, authors, funding and every citing paper · PMID 27311491